Mohammed Salhab, MD Make an Appointment Ask a Question Refer Patient Mohammed Salhab, MD, is an oncologist and a hematologist at National Jewish Health. Dr. Salhab is in the Division of Oncology and Department of Medicine. Director of Community Oncology Practices Assistant Professor Northern Hematology-Oncology Western Hematology-Oncology Division of Oncology Department of Medicine 5280 Top Doctors 2022 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2019-2020 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2020 — Castle Connolly Medical, Ltd. Email Profile Print Profile Overview Contact Info & Locations Patient Ratings & Comments Programs & Services Cancer Care Department of Medicine Division of Oncology Specialties & Conditions Blood Disorders Head & Neck Cancer Hematology Lung Cancer Oncology Research Areas Lung Cancer Special Interests Clinical research for lung cancer, small cell and non small cell lung cancer. Education Education 2004 - 2010 Jordan University, Residency Memorial Hospital Of RI/Brown University Internal Medicine, Fellowship University of Massachusetts Medical School Hematology and Medical Oncology, Awards & Recognition 2015: Best senior resident Board Certification 2015: Internal Medicine 2018: Hematology 2018: Medical Oncology Professional Memberships American Society of Clinical Oncology American Society of Hematology Society for Immunotherapy of Cancer Publications Salhab M, Migdady Y, Donahue M, Xiong Y, Dresser K, Walsh W, Chen BJ, Liebmann J. Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. J Immunother Cancer. 2018 May 29;6(1):42 16. Zhu X, Salhab M, Donahue M and Walsh W. Pembrolizumab for platinum refractory small cell carcinoma of the prostate, case report. Hematol Med Oncol, 2018 Salhab M, Tomaszewicz K, Meng X, Mathew C et all. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in Appendiceal mucinous neoplasms. Human pathology, 2018 Epperla, N., Maddocks, K. J., Salhab, M., Chavez, J. C., Reddy, N., Karmali, R., Umyarova, E., Bachanova, V., Costa, C., Glenn, M., Calzada, O., Xavier, A. C., Zhou, Z., Hossain, N. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Barta, S. K., Chhabra, S., Lansigan, F., Mehta, A., Jaglal, M. V., Evans, A., Flowers, C. R., Cohen, J. B., Fenske, T. S., Hamadani, M. and Costa, L. J. (2017), C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits”and outcomes with subsequent therapy. Cancer. Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, Muba-rak S, Salhab M, Jiang Y, Granwehr B, Adachi JA, Raad I. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries. Cancer. 2012 Sep; 118 (18): 4627-4633 Ask a Question through MyChart Sign in to your MyChart account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Western Hematology Oncology Office: 303.232.0602Northern Hematology Oncology Office: 303.650.4042 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.